Thank you.
Thank you.
One has to wonder what they are really up to. Digital ID and experimenting on ignorant people Joseph Mengele? We already know Gates is part of the population reduction crowd so he can't possibly be doing this to help people. That would be contrary to his stated beliefs in world population numbers. Now what about MasterCard's Foundation? I wasn't aware that big financial institutions could have foundations.
SEATTLE, March 10, 2020 – The Bill & Melinda Gates Foundation, Wellcome, and Mastercard today committed up to $125 million in seed funding to speed-up the response to the COVID-19 epidemic by identifying, assessing, developing, and scaling-up treatments. The partners are committed to equitable access, including making products available and affordable in low-resource settings. The COVID-19 Therapeutics Accelerator will play a catalytic role by accelerating and evaluating new and repurposed drugs and biologics to treat patients with COVID-19 in the immediate term, and other viral pathogens in the longer-term. Currently there are no broad-spectrum antivirals or immunotherapies available for the fight against emerging pathogens, and none approved for use on COVID-19.
>One has to wonder what they are really up to. Digital ID and experimenting on ignorant people Joseph Mengele? We already know Gates is part of the population reduction crowd so he can't possibly be doing this to help people. That would be contrary to his stated beliefs in world population numbers. Now what about MasterCard's Foundation? I wasn't aware that big financial institutions could have foundations.
SEATTLE, March 10, 2020 – The Bill & Melinda Gates Foundation, Wellcome, and Mastercard today committed up to $125 million in seed funding to speed-up the response to the COVID-19 epidemic by identifying, assessing, developing, and scaling-up treatments. The partners are committed to equitable access, including making products available and affordable in low-resource settings. The COVID-19 Therapeutics Accelerator will play a catalytic role by accelerating and evaluating new and repurposed drugs and biologics to treat patients with COVID-19 in the immediate term, and other viral pathogens in the longer-term. Currently there are no broad-spectrum antivirals or immunotherapies available for the fight against emerging pathogens, and none approved for use on COVID-19.
(post is archived)